Additionally, the 36-month beta value for NRXP is 1.25. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NRXP is 9.24M and currently, short sellers hold a 6.12% ratio of that float. The average trading volume of NRXP on December 18, 2024 was 143.50K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NRXP) stock’s latest price update
NRX Pharmaceuticals Inc (NASDAQ: NRXP)’s stock price has soared by 36.67 in relation to previous closing price of 1.20. Nevertheless, the company has seen a gain of 35.54% in its stock price over the last five trading days. zacks.com reported 2024-11-27 that NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
NRXP’s Market Performance
NRX Pharmaceuticals Inc (NRXP) has experienced a 35.54% rise in stock performance for the past week, with a 37.82% rise in the past month, and a 1.23% rise in the past quarter. The volatility ratio for the week is 11.02%, and the volatility levels for the past 30 days are at 8.54% for NRXP. The simple moving average for the past 20 days is 30.18% for NRXP’s stock, with a -37.10% simple moving average for the past 200 days.
NRXP Trading at 28.30% from the 50-Day Moving Average
After a stumble in the market that brought NRXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.64% of loss for the given period.
Volatility was left at 8.54%, however, over the last 30 days, the volatility rate increased by 11.02%, as shares surge +26.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.33% upper at present.
During the last 5 trading sessions, NRXP rose by +35.54%, which changed the moving average for the period of 200-days by -68.46% in comparison to the 20-day moving average, which settled at $1.2598. In addition, NRX Pharmaceuticals Inc saw -64.35% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NRXP
Current profitability levels for the company are sitting at:
- -2559.5 for the present operating margin
- 0.62 for the gross margin
The net margin for NRX Pharmaceuticals Inc stands at -2547.5. The total capital return value is set at 1.29. Equity return is now at value -682.61, with -231.96 for asset returns.
Based on NRX Pharmaceuticals Inc (NRXP), the company’s capital structure generated -0.55 points at debt to capital in total, while cash flow to debt ratio is standing at -1.85. The debt to equity ratio resting at -0.35. The interest coverage ratio of the stock is -66.05.
Currently, EBITDA for the company is -30.02 million with net debt to EBITDA at -0.26. When we switch over and look at the enterprise to sales, we see a ratio of 3107.17. The receivables turnover for the company is 1.33for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.20.
Conclusion
In conclusion, NRX Pharmaceuticals Inc (NRXP) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
